🇫🇷 SAN.PA — Sanofi
Healthcare CompraPrecio actual
76,26 EUR
Máx. histórico
110,88
543 días
Caída desde máximo
-31,22%
Rango 52 semanas
71,25 – 91,15
Variación hoy
-0,01%
Cierre anterior
76,27
Rango de hoy
75,90 – 76,65
Volumen hoy
1.490.914
- Nombre completo
- Sanofi
- Divisa
- EUR
- Mercado
- Paris
- Sector
- Healthcare
- Industria
- Drug Manufacturers - General
- Empleados
- 74.846
- PER ⓘ
- 23,54 (puede no estar actualizado)
- Dividend yield
- 5,40% (puede no estar actualizado)
- Precio objetivo analistas
- 94,28 EUR (puede no estar actualizado)
- Primera cotización
- 03/01/2000
- Precio actualizado
- hace 2 días
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Fecha de pago | Importe por participación |
|---|---|
| 16/05/2011 | 2,5000 EUR |
| 20/05/2010 | 2,4000 EUR |
| 23/04/2009 | 2,2000 EUR |
| 16/05/2008 | 2,0700 EUR |
| 07/06/2007 | 1,7500 EUR |
| 29/11/2006 | 0,2668 EUR |
| 07/06/2006 | 1,5200 EUR |
| 29/11/2005 | 0,2409 EUR |
| 07/06/2005 | 1,2000 EUR |
| 30/09/2004 | 0,0750 EUR |
| 05/05/2004 | 1,4550 EUR |
| 02/06/2003 | 0,8400 EUR |
| 03/06/2002 | 0,6600 EUR |
| 01/06/2001 | 0,4400 EUR |
| 05/06/2000 | 0,3200 EUR |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/11/2003 | 53,91 | 54,30 | 53,36 | 53,76 | +0,00% | 1,75% | 1.317.024 |
| 05/11/2003 | 53,96 | 54,40 | 53,61 | 53,76 | -1,10% | 1,47% | 1.210.474 |
| 04/11/2003 | 53,71 | 54,60 | 53,61 | 54,35 | +0,64% | 1,85% | 1.113.450 |
| 03/11/2003 | 52,91 | 54,30 | 52,91 | 54,01 | +1,97% | 2,63% | 1.373.812 |
| 31/10/2003 | 53,11 | 53,51 | 51,72 | 52,96 | -0,93% | 3,37% | 2.575.097 |
| 30/10/2003 | 53,31 | 53,91 | 52,61 | 53,46 | +0,28% | 2,43% | 1.288.401 |
| 29/10/2003 | 53,26 | 53,41 | 52,31 | 53,31 | +0,85% | 2,05% | 1.170.914 |
| 28/10/2003 | 52,46 | 53,06 | 52,26 | 52,86 | +1,14% | 1,52% | 1.244.518 |
| 27/10/2003 | 51,77 | 53,16 | 51,57 | 52,26 | +1,16% | 3,07% | 1.124.481 |
| 24/10/2003 | 51,32 | 51,92 | 51,17 | 51,67 | +0,29% | 1,45% | 1.073.770 |
| 23/10/2003 | 51,37 | 51,92 | 50,87 | 51,52 | -1,33% | 2,03% | 2.316.084 |
| 22/10/2003 | 52,71 | 52,96 | 51,57 | 52,21 | -2,69% | 2,64% | 2.424.876 |
| 21/10/2003 | 53,46 | 54,35 | 53,31 | 53,66 | +1,31% | 1,95% | 2.530.473 |
| 20/10/2003 | 52,61 | 53,21 | 52,02 | 52,96 | +0,76% | 2,27% | 1.391.864 |
| 17/10/2003 | 52,76 | 53,36 | 52,51 | 52,56 | -0,09% | 1,60% | 1.434.677 |
| 16/10/2003 | 52,41 | 53,31 | 52,02 | 52,61 | -0,47% | 2,47% | 1.177.137 |
| 15/10/2003 | 52,96 | 53,41 | 52,31 | 52,86 | +0,38% | 2,07% | 1.233.898 |
| 14/10/2003 | 53,26 | 53,41 | 52,02 | 52,66 | -1,21% | 2,61% | 1.408.104 |
| 13/10/2003 | 52,61 | 53,31 | 52,21 | 53,31 | +1,52% | 2,08% | 1.270.936 |
| 10/10/2003 | 53,11 | 53,11 | 51,87 | 52,51 | -1,12% | 2,34% | 1.493.411 |
| 09/10/2003 | 51,72 | 53,11 | 51,37 | 53,11 | +2,50% | 3,37% | 1.684.669 |
| 08/10/2003 | 51,92 | 52,91 | 51,42 | 51,82 | -0,76% | 2,87% | 1.323.216 |
| 07/10/2003 | 53,06 | 53,06 | 51,47 | 52,21 | -1,13% | 3,00% | 2.058.940 |
| 06/10/2003 | 53,91 | 54,25 | 52,56 | 52,81 | -2,57% | 3,14% | 1.321.904 |
| 03/10/2003 | 51,82 | 54,20 | 51,72 | 54,20 | +4,41% | 4,80% | 1.726.099 |
| 02/10/2003 | 52,56 | 52,81 | 51,42 | 51,92 | -0,85% | 2,65% | 1.741.224 |
| 01/10/2003 | 51,37 | 52,46 | 50,52 | 52,36 | +0,86% | 3,78% | 3.107.501 |
| 30/09/2003 | 52,17 | 52,51 | 51,62 | 51,92 | -0,67% | 1,72% | 2.598.297 |
| 29/09/2003 | 52,76 | 53,46 | 51,97 | 52,26 | -1,41% | 2,83% | 2.950.054 |
| 26/09/2003 | 52,81 | 53,36 | 52,61 | 53,01 | -0,47% | 1,41% | 1.739.100 |